Centivax

About

Centivax is a biotechnology company based in South San Francisco, California, founded in 2020. The company is dedicated to advancing global health by developing broad-spectrum vaccines and antivenoms. Its flagship product, Centi-Flu, is a universal flu vaccine aimed at providing long-lasting immunity against all influenza strains and is currently in pre-clinical development. Centivax is also focused on creating broad-spectrum anti-venom and anti-infectives to address evolving health threats. To enhance the development of its products, Centivax has partnered with Emery Pharma to ensure the clinical readiness of Centi-Flu. The company has successfully raised $10.99 million in funding from notable investors, including the Bill & Melinda Gates Foundation. Under the leadership of CEO Jacob Glanville, Centivax is committed to tackling global health challenges, particularly in the context of pandemics and infectious diseases.